CAR T-Cell Therapy in Multiple Myeloma
The introduction of CAR (chimeric antigen receptor) T-cell therapy into clinical practice has revolutionized the treatment landscape of relapsed/refractory multiple myeloma (RRMM). At present, two B-cell maturation antigen (BCMA)-targeted CAR T-cell therapies, idecabtagene vicleucel and ciltacabtagene autoleucel, are used in clinical practice, but only ciltacabtagene autoleucel is approved in Brazil. In this review, we explore the advantages and challenges of integrating CAR T-cell therapy earlier in the RRMM treatment course.
Authors
- Ângelo Maiolino (ORCID: https://orcid.org/0000-0003-0140-9548)
- João Tadeu Damian Souto Filho (ORCID: https://orcid.org/0000-0003-2641-1425)
- Mariana Nassif Kerbauy (ORCID: https://orcid.org/0000-0002-4441-9212)
- Abrahão Elias Hallack Neto (ORCID: https://orcid.org/0000-0001-6671-9710)
- Edvan de Queiroz Crusoé (ORCID: https://orcid.org/0000-0002-8599-4731)
- Roberto José Pessoa de Magalhães Filho (ORCID: https://orcid.org/0000-0001-7432-3732)
- Vania Tietsche de Moraes Hungria (ORCID: https://orcid.org/0000-0002-4327-1957)
- Fernando Vieira Pericole de Souza
Institutions
- Universidade Federal de Juiz de Fora (BR)
- Universidade Federal do Rio de Janeiro (BR)
- Universidade Federal da Bahia (BR)
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Hospital Israelita Albert Einstein (BR)
- São Germano Oncologia (BR)
- Prefeitura Municipal de Campos dos Goytacazes (BR)
Publication Details
- Journal
- JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
- Published
- 2026-11-20
- DOI
- https://doi.org/10.46765/2675-374x.2025v7n1e390
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00